SYN [AMEX]
Synthetic Biologics, Inc.
Index- P/E- EPS (ttm)-0.12 Insider Own0.50% Shs Outstand132.04M Perf Week15.84%
Market Cap29.84M Forward P/E- EPS next Y-0.20 Insider Trans0.00% Shs Float- Perf Month3.24%
Income-16.00M PEG- EPS next Q-0.04 Inst Own8.30% Short Float- Perf Quarter-21.45%
Sales- P/S- EPS this Y71.20% Inst Trans-4.65% Short Ratio1.29 Perf Half Y-16.97%
Book/sh0.49 P/B0.46 EPS next Y-28.60% ROA-20.50% Target Price1.62 Perf Year-60.41%
Cash/sh0.43 P/C0.53 EPS next 5Y- ROE-22.60% 52W Range0.18 - 0.57 Perf YTD-16.97%
Dividend- P/FCF- EPS past 5Y54.80% ROI- 52W High-61.21% Beta1.55
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low23.39% ATR0.02
Employees16 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)57.19 Volatility12.47% 7.76%
OptionableNo Debt/Eq0.00 EPS Q/Q75.50% Profit Margin- Rel Volume0.39 Prev Close0.23
ShortableYes LT Debt/Eq0.00 EarningsMay 16 BMO Payout- Avg Volume868.37K Price0.22
Recom2.00 SMA208.80% SMA501.18% SMA200-26.46% Volume299,766 Change-1.73%
Jan-06-17Reiterated FBR & Co. Outperform $5 → $6
May-06-16Reiterated FBR Capital Outperform $10 → $9
Feb-26-16Initiated FBR Capital Outperform $10
Oct-13-15Initiated RBC Capital Mkts Outperform $8
Mar-16-15Downgrade Maxim Group Buy → Hold $3
Mar-02-15Reiterated Maxim Group Buy $6 → $3
Mar-19-14Reiterated Maxim Group Buy $3 → $6
Sep-30-13Initiated Maxim Group Buy $3
Jun-25-13Initiated Ascendiant Capital Markets Buy $2.25
May-16-22 08:00AM  
May-10-22 12:24PM  
08:00AM  
May-09-22 08:00AM  
May-05-22 08:00AM  
May-04-22 08:00AM  
Mar-29-22 09:44AM  
Mar-28-22 04:05PM  
Mar-23-22 08:00AM  
Mar-22-22 04:05PM  
Mar-16-22 04:05PM  
Mar-11-22 08:00AM  
Mar-10-22 04:30PM  
Feb-09-22 07:15AM  
Feb-08-22 07:15AM  
Jan-26-22 04:05PM  
Dec-14-21 07:00AM  
Nov-03-21 04:10PM  
Oct-26-21 07:00AM  
Oct-21-21 07:00AM  
Oct-06-21 04:30PM  
Sep-21-21 04:30PM  
Sep-10-21 12:19PM  
Aug-05-21 04:10PM  
Aug-03-21 07:00AM  
Jul-28-21 07:00AM  
Jun-29-21 07:00AM  
Jun-14-21 03:35PM  
May-26-21 07:00AM  
May-05-21 04:10PM  
02:30PM  
Apr-28-21 07:00AM  
Apr-14-21 07:00AM  
Apr-01-21 07:00AM  
Mar-04-21 04:10PM  
02:30PM  
Feb-04-21 05:38AM  
Dec-22-20 07:00AM  
Nov-24-20 07:00AM  
Nov-16-20 07:00AM  
Nov-12-20 07:00AM  
Nov-10-20 04:15PM  
02:45PM  
Nov-03-20 04:30PM  
Oct-02-20 07:00AM  
Jun-30-20 07:00AM  
Jun-15-20 11:41AM  
May-27-20 07:00AM  
May-13-20 12:20PM  
May-06-20 09:55AM  
May-05-20 04:15PM  
Apr-28-20 04:30PM  
Mar-16-20 03:41PM  
Feb-26-20 12:29PM  
Feb-23-20 02:26PM  
Feb-20-20 04:15PM  
Feb-07-20 04:30PM  
Feb-06-20 01:53PM  
Jan-07-20 07:00AM  
Dec-30-19 05:54AM  
Dec-24-19 07:29AM  
Nov-30-19 09:39AM  
Nov-27-19 04:30PM  
Nov-21-19 12:21AM  
Nov-14-19 11:23AM  
Nov-06-19 12:02PM  
Nov-04-19 04:10PM  
Oct-28-19 04:30PM  
Sep-26-19 07:00AM  
Sep-06-19 11:24AM  
Sep-01-19 10:50PM  
Aug-28-19 01:12PM  
Aug-20-19 09:46AM  
Aug-08-19 04:15PM  
Aug-01-19 07:00AM  
Jul-01-19 07:00AM  
May-27-19 03:14PM  
May-24-19 10:25AM  
May-22-19 12:55PM  
May-08-19 06:02PM  
04:10PM  
Apr-30-19 04:30PM  
Apr-20-19 03:38AM  
Feb-27-19 04:10PM  
03:05PM  
02:55PM  
02:53PM  
Feb-26-19 10:38AM  
Feb-19-19 04:30PM  
Jan-03-19 07:00AM  
Dec-18-18 10:38AM  
Dec-04-18 12:00PM  
Nov-27-18 08:20AM  
Nov-22-18 09:10AM  
Nov-21-18 09:25AM  
07:00AM  
Nov-08-18 06:02PM  
04:10PM  
Oct-30-18 04:30PM  
Oct-18-18 08:40AM  
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.